A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus

Markus Suckfüll, Michael Althaus, Barbara Ellers-Lenz, Alexander Gebauer, Roman Görtelmeyer, Pawel J Jastreboff, Hans J Moebius, Tanja Rosenberg, Hermann Russ, Yvonne Wirth, Hagen Krueger, Markus Suckfüll, Michael Althaus, Barbara Ellers-Lenz, Alexander Gebauer, Roman Görtelmeyer, Pawel J Jastreboff, Hans J Moebius, Tanja Rosenberg, Hermann Russ, Yvonne Wirth, Hagen Krueger

Abstract

Background: Neramexane is a new substance that exhibits antagonistic properties at α9α10 cholinergic nicotinic receptors and N-methyl-D-aspartate receptors, suggesting potential efficacy in the treatment of tinnitus.

Methods: A total of 431 outpatients with moderate to severe subjective tinnitus (onset 3-18 months before screening) were assigned randomly to receive either placebo or neramexane mesylate (25 mg/day, 50 mg/day and 75 mg/day) for 16 weeks, with assessment at 4-week intervals. The primary (intention-to-treat) efficacy analysis was based on the change from baseline in Week 16 in the total score of the adapted German short version of the validated Tinnitus Handicap Inventory questionnaire (THI-12).

Results: Compared with placebo, the largest improvement was achieved in the 50 mg/d neramexane group, followed by the 75 mg/d neramexane group. This treatment difference did not reach statistical significance at the pre-defined endpoint in Week 16 (p = 0.098 for 50 mg/d; p = 0.289 for 75 mg/d neramexane), but consistent numerical superiority of both neramexane groups compared with placebo was observed. Four weeks after the end of treatment, THI-12 scores in the 50 mg/d group were significantly better than those of the controls. Secondary efficacy variables supported this trend, with p values of < 0.05 for the 50 mg/d neramexane group associated with the functional-communicational subscores of the THI-12 and the assessments of tinnitus annoyance and tinnitus impact on life as measured on an 11-point Likert-like scale. No relevant changes were observed for puretone threshold, for tinnitus pitch and loudness match, or for minimum masking levels. The 25 mg/d neramexane group did not differ from placebo. Neramexane was generally well tolerated and had no relevant influence on laboratory values, electrocardiography and vital signs. Dizziness was the most common adverse event and showed a clear dose-dependence.

Conclusions: This study demonstrated the safety and tolerability of neramexane treatment in patients with moderate to severe tinnitus. The primary efficacy variable showed a trend towards improvement of tinnitus suffering in the medium- and high-dose neramexane groups. This finding is in line with consistent beneficial effects observed in secondary assessment variables. These results allow appropriate dose selection for further studies.

Trial registration: ClinicalTrials.gov NCT00405886.

Figures

Figure 1
Figure 1
Study flow chart
Figure 2
Figure 2
Patient disposition, flow chart
Figure 3
Figure 3
Mean course of the primary efficacy variable (THI-12 score) 1. Intention-to-treat, last observation carried forward. 2. Difference of least square means 50 mg vs. placebo and p-values from ANCOVA with treatment and center as factor, baseline as covariate 3. Difference from baseline, * p < 0.05

References

    1. Pilgram M, Rychlik R, Lebisch H, Siedentop H, Goebel G, Kirchhoff D. Tinnitus in der Bundesrepublik Deutschland - eine repräsentative epidemiologische Studie. HNO aktuell. 1999;7:261–265.
    1. Eggermont JJ. Tinnitus: neurobiological substrates. Drug Discov Today. 2005;10:1283–1290. doi: 10.1016/S1359-6446(05)03542-7.
    1. Lockwood AH, Salvi RJ, Coad ML, Towsley ML, Wack DS, Murphy BW. The functional neuroanatomy of tinnitus: evidence for limbic system links and neural plasticity. Neurology. 1998;50:114–120.
    1. Folmer RL, Griest SE, Meikle MB, Martin WH. Tinnitus severity, loudness, and depression. Otolaryngol Head Neck Surg. 1999;121:48–51. doi: 10.1016/S0194-5998(99)70123-3.
    1. Henry JA, Meikle MB. Psychoacoustic measures of tinnitus. J Am Acad Audiol. 2000;11:138–155.
    1. Meikle MB, Vernon J, Johnson RM. The perceived severity of tinnitus; some observations concerning a large population of tinnitus clinic patients. Otolaryngol Head Neck Surg. 1984;92:689–696.
    1. Hiller W, Goebel G. When tinnitus loudness and annoyance are discrepant: audiological characteristics and psychological profile. Audiol Neurootol. 2007;12:391–400. doi: 10.1159/000106482.
    1. Basile AS, Huang JM, Xie C, Webster D, Berlin C, Skolnick P. N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss. Nat Med. 1996;2:1338–1343. doi: 10.1038/nm1296-1338.
    1. Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF, Boulter J. alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci USA. 2001;98:3501–3506. doi: 10.1073/pnas.051622798.
    1. Elgoyhen AB, Johnson DS, Boulter J, Vetter DE, Heinemann S. Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell. 1994;79:705–715. doi: 10.1016/0092-8674(94)90555-X.
    1. Elgoyhen AB, Katz E, Fuchs PA. The nicotinic receptor of cochlear hair cells: a possible pharmacotherapeutic target? Biochem Pharmacol. 2009;78:712–719. doi: 10.1016/j.bcp.2009.05.023.
    1. Veuillet E, Bazin F, Collet L. Objective evidence of peripheral auditory disorders in learning-impaired children. J Audiol Med. 1999;8:18–29.
    1. Parsons CG, Danysz W, Bartmann A, Spielmanns P, Frankiewicz T, Hesselink M, Eilbacher B, Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology. 1999;38:85–108. doi: 10.1016/S0028-3908(98)00161-0.
    1. Plazas PV, Savino J, Kracun S, Gomez-Casati ME, Katz E, Parsons CG, Millar NS, Elgoyhen AB. Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by Neramexane, an open channel blocker of N methyl-D aspartate receptors. Eur J Pharmacol. 2007;566:11–19. doi: 10.1016/j.ejphar.2007.03.026.
    1. Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J. Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr Pharm Des. 2002;8:835–843. doi: 10.2174/1381612024607117.
    1. Rammes G, Rupprecht R, Ferrari U, Zieglgänsberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001;306:81–84. doi: 10.1016/S0304-3940(01)01872-9.
    1. Noble W. Treatments for tinnitus. Trends Amplif. 2008;12:236–241. doi: 10.1177/1084713808320552.
    1. Greimel KV, Leibetseder M, Unterrainer J, Biesinger E, Albegger K. Der Tinnitus-Beeinträchtigungs-Fragebogen (TBF-12). Übersetzung und Adaption. Verhaltenstherapie und Verhaltensmedizin. 2000;21:39–49.
    1. Korbel US, Görtelmeyer R, Elkin E. 4th Tinnitus Research Initiative Meeting 2010. Dallas, Texas; Intercultural validation of the Tinnitus Handicap Inventory 12 (THI-12)
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Biesinger E, Hesse G, Mazurek B, Zenner HP, Brusis T, Goebel G, Kröner-Herwig B, Michel O, Arnold W. AWMF online: Leitlinien der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie: Tinnitus.
    1. Budd RJ, Pugh R. Tinnitus coping style and its relationship to tinnitus severity and emotional distress. J Psychosomatic Res. 1996;41:327–335. doi: 10.1016/S0022-3999(96)00171-7.
    1. Langguth B, Goodey R, Azevedo A, Bjorne A, Cacace A, Crocetti A, Del Bo L, De Ridder D, Diges I, Elbert T, Flor H, Herraiz C, Ganz Sanchez T, Eichhammer P, Figueiredo R, Hajak G, Kleinjung T, Landgrebe M, Londero A, Lainez MJ, Mazzoli M, Meikle MB, Melcher J, Rauschecker JP, Sand PG, Struve M, Van de Heyning P, Van Dijk P, Vergara R, editor. Tinnitus Research Initiative Meeting: XX-YY July 2006; Regensburg, Germany. Prog Brain Res. Vol. 166. 2007. Consensus for tinnitus patient assessment and treatment outcome measurement; pp. 525–36.
    1. Figueiredo RR, Langguth B, Mello de Oliveira P, Aparecida de Azevedo A. Tinnitus treatment with memantine. Otolaryngol Head Neck Surg. 2008;138:492–496. doi: 10.1016/j.otohns.2007.11.027.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever